Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: scherer sj. J Natl Cancer Inst. 2015 Feb 24;107(3):dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25713148 Free PMC article.
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Volz NB, et al. Among authors: scherer sj. Pharmacogenomics J. 2015 Feb;15(1):69-76. doi: 10.1038/tpj.2014.40. Epub 2014 Jul 29. Pharmacogenomics J. 2015. PMID: 25069475 Clinical Trial.
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.
Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. Sunakawa Y, et al. Among authors: scherer sj. Ann Oncol. 2015 Dec;26(12):2450-6. doi: 10.1093/annonc/mdv474. Epub 2015 Sep 28. Ann Oncol. 2015. PMID: 26416897 Free PMC article. Clinical Trial.
Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.
Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. Stremitzer S, et al. Among authors: scherer sj. Mol Cancer Ther. 2016 Nov;15(11):2814-2821. doi: 10.1158/1535-7163.MCT-16-0275. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535973 Free PMC article.
Markers of response for the antiangiogenic agent bevacizumab.
Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Lambrechts D, et al. Among authors: scherer sj. J Clin Oncol. 2013 Mar 20;31(9):1219-30. doi: 10.1200/JCO.2012.46.2762. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401453 Review.
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C. Brauer MJ, et al. Among authors: scherer sj. Clin Cancer Res. 2013 Jul 1;19(13):3681-92. doi: 10.1158/1078-0432.CCR-12-3635. Epub 2013 May 17. Clin Cancer Res. 2013. PMID: 23685835
46 results